Personalized and targeted therapies

被引：0
作者：
Wisniewska, Magdalena [3 ,4 ]
Wisniewski, Michal [5 ]
Lewandowska, Marzena A. [1 ,2 ]
机构：
[1] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Dept Thorac Surg & Tumors, Torun, Poland
[2] Innovat Med Forum Oncol Ctr, Dept Mol Oncol & Genet, Bydgoszcz, Poland
[3] Nicolaus Copernicus Univ, Coll Med Bydgoszcz, Dept Oncol & Brachytherapy, Torun, Poland
[4] Oncol Ctr, Dept Clin Oncol, Bydgoszcz, Poland
[5] Oncol Ctr, Outpatient Chemotherapy Dept, Bydgoszcz, Poland
来源：
PHYSICAL SCIENCES REVIEWS | 2021年
关键词：
biomarker; predictive biomarkers; tailored treatment; targeted therapies; CELL LUNG-CANCER; METASTATIC COLORECTAL-CANCER; ANAPLASTIC LYMPHOMA KINASE; GROWTH-FACTOR RECEPTOR; WILD-TYPE KRAS; BREAST-CANCER; OPEN-LABEL; RAS MUTATIONS; DOUBLE-BLIND; MONOCLONAL-ANTIBODY;
D O I：
10.1515/psr-2019-0057
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Biomarker is defined as indicator of normal or pathogenic biological process or response to an intervention or exposure. There are several categories of biomarkers but predictive biomarkers play the most important role in the treatment of neoplasms. In some cancers there may be more than one potential biomarker, and their identification determines the treatment of the patient. Identification of predictive biomarkers allows the development of novel targeted therapies resulting in tailored treatment. In this chapter we discuss most important predictive biomarkers used in contemporary oncology for which there is approved therapies.
引用
收藏
页码：2103 / 2126
页数：24
相关论文
共 120 条
  • [1] The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer
    Acquaviva, Jaime
    Wong, Ricky
    Charest, Al
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1795 (01): : 37 - 52
  • [2] Allred C, 2009, J NATL COMPR CANC NE, V7, pS1
  • [3] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Amado, Rafael G.
    Wolf, Michael
    Peeters, Marc
    Van Cutsem, Eric
    Siena, Salvatore
    Freeman, Daniel J.
    Juan, Todd
    Sikorski, Robert
    Suggs, Sid
    Radinsky, Robert
    Patterson, Scott D.
    Chang, David D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1626 - 1634
  • [4] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) : 1929 - 1940
  • [5] MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    Awad, Mark M.
    Oxnard, Geoffrey R.
    Jackman, David M.
    Savukoski, Daniel O.
    Hall, Dimity
    Shivdasani, Priyanka
    Heng, Jennifer C.
    Dahlberg, Suzanne E.
    Anne, Pasi A. J.
    Verma, Suman
    Christensen, James
    Hammerman, Peter S.
    Sholl, Lynette M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) : 721 - +
  • [6] Bang YJ, 2010, LANCET, V376, P1302
  • [7] Blockade of programmed death-1 Ligands on dendritic cells enhances T cell activation and cytokine production
    Brown, JA
    Dorfman, DM
    Ma, FR
    Sullivan, EL
    Munoz, O
    Wood, CR
    Greenfield, EA
    Freeman, GJ
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (03) : 1257 - 1266
  • [8] The distinctive nature of HER2-positive breast cancers
    Burstein, HJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16) : 1652 - 1654
  • [9] Biomarker definitions and their applications
    Califf, Robert M.
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2018, 243 (03) : 213 - 221
  • [10] 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
    Cameron, David
    Piccart-Gebhart, Martine J.
    Gelber, Richard D.
    Procter, Marion
    Goldhirsch, Aron
    de Azambuja, Evandro
    Castro, Gilberto, Jr.
    Untch, Michael
    Smith, Ian
    Gianni, Luca
    Baselga, Jose
    Al-Sakaff, Nedal
    Lauer, Sabine
    McFadden, Eleanor
    Leyland-Jones, Brian
    Bell, Richard
    Dowsett, Mitch
    Jackisch, Christian
    [J]. LANCET, 2017, 389 (10075) : 1195 - 1205
12345678910